Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Multicenter Single-arm Study of Denosumab in Children With Osteogenesis Imperfecta
2014-000184-40Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of denosumab in osteogenesis imperfecta (OI), sponsored by Amgen. Primary endpoint: Change in lumbar spine BMD Z-score at 12 months. Started Aug 2014; status: completed.
02
Drugs
denosumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2014-000184-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000184-40.